Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BWF
|
|||
| Former ID |
DNCL001689
|
|||
| Drug Name |
AGN-XX/YY
|
|||
| Synonyms |
Rezatomidine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z] | Phase 2 | [1] | |
| Fibromyalgia [ICD-11: MG30.01; ICD-10: M79.7] | Phase 2 | [1] | ||
| Company |
ACADIA Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H16N2S
|
|||
| Canonical SMILES |
CC1=C(C(=CC=C1)C(C)C2=CNC(=S)N2)C
|
|||
| InChI |
1S/C13H16N2S/c1-8-5-4-6-11(9(8)2)10(3)12-7-14-13(16)15-12/h4-7,10H,1-3H3,(H2,14,15,16)/t10-/m0/s1
|
|||
| InChIKey |
WQXVKEDUCPMRRI-JTQLQIEISA-N
|
|||
| CAS Number |
CAS 847829-38-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Agonist | [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ACADIA Pharmaceuticals. | |||
| REF 2 | Patent WO2008058220 A2. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.